ACCESS Newswire

AlzeCure Pharma

Share
Alzecure Gives Live Streamed Strategy Update on Alzheimer’s Disease and NeuroreStore on September 1

STOCKHOLM, SE / ACCESSWIRE / August 17, 2021 / AlzeCure Pharma (STO:ALZCUR) (FRA:AC6)

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer's disease and pain, today announced that it will give a live streamed update focusing on its project platform NeuroRestore and Alzheimer's disease on September 1 at 09:00 CEST. The presentation will be followed by a Q&A session and discussion led by Fredrik Thor, analyst at Redeye.

Martin Jönsson, CEO at AlzeCure, together with Johan Sandin, CSO, and Pontus Forsell, Head of Discovery & Research, will present the NeuroRestore platform and the clinical development plan for the company's leading drug candidate ACD856. In addition, Professor Maria Eriksdotter, M.D., PhD, at the Karolinska Institute, will give her view on the neurotrophins BDNF / NGF and potential link to and therapeutic role in Alzheimer's disease.

Watch the livestream on September 1 at 09:00 CEST via:
https://www.redeye.se/events/816325/strategy-update-alzecure-pharma-2

More information and registration:
https://www.lyyti.in/Strategy_Update_AlzeCure_Pharma_4394

The presentation will be held in English.

For more information, please contact

Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com

About AlzeCure Pharma AB (publ)

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is extremely limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.

NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure® aims to pursue its own projects through preclinical research and development to early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies.

FNCA Sweden AB, +46(0)8 528 00 399 info@fnca.se , is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se .

Attachments

AlzeCure gives live streamed strategy update on Alzheimer's disease and NeuroRestore on September 1

SOURCE: AlzeCure Pharma



View source version on accesswire.com:
https://www.accesswire.com/660083/Alzecure-Gives-Live-Streamed-Strategy-Update-on-Alzheimers-Disease-and-NeuroreStore-on-September-1

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

DASA, Latin America's Largest Diagnostic Provider, Selects AGFA HealthCare's Enterprise Imaging Platform in Flagship Agreement1.7.2025 10:00:00 CEST | Press release

AGFA HealthCare is proud to announce a landmark achievement: the adoption of its Enterprise Imaging Platform by the largest integrated health network in Latin America - and the fifth largest globally. MORTSEL, BE / ACCESS Newswire / July 1, 2025 / DASA (Diagnósticos da América S.A.) operates an extensive hospital network across Brazil and Argentina, bringing together more than 40 healthcare provider brands. In 2024, DASA and Amil announced the creation of a joint venture that consolidates 25 hospitals and over 4,400 beds, making DASA the second largest hospital group in Brazil. With 321 branches across Brazil, DASA delivers more than 15.2 million clinical studies per year, serves 55,000 patients daily, and processes around 10 million tests monthly - solidifying its leading role in healthcare delivery across the region.AGFA HealthCare After a thorough evaluation process, DASA selected AGFA HealthCare's Enterprise Imaging Platform. Key moments in the decision journey included live demons

Clean Air Metals Files Interim Financial Statements for the Three Months Ended April 30, 202530.6.2025 23:40:00 CEST | Press release

THUNDER BAY, ON / ACCESS Newswire / June 30, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF) announces that it has filed its unaudited consolidated interim financial statements and management's discussion and analysis for the three-month period ended April 30, 2025, available for viewing on www.sedarplus.ca. Financial Highlights Total assets as at April 30, 2025 of $37,507,184 Total cash as at April 30, 2025 of $2,475,945 Working capital deficiency as at April 30, 2025 of $527,130 Shareholder's equity as at April 30, 2025 of $33,668,042 During the quarter, the Company incurred $584,284 in cost for exploration activities at the Thunder Bay North project. The team performed drilling and follow-up geophysics activities at the Current Deposit, that were focused on expanding the high-grade ballrooms in the Lower Current and Bridge zones. The results of this program were critical in aiding the Company towards developing a revised high-grade

Karbon-X Acquires ALLCOT, Expanding Global Climate Solutions Platform30.6.2025 15:00:00 CEST | Press release

The acquisition unites climate policy expertise and emissions strategy with digital infrastructure and delivery at scale - accelerating trusted, measurable climate action worldwide. CALGARY, AB / ACCESS Newswire / June 30, 2025 / Karbon-X (OTCQX:KARX), an end-to-end climate solutions company, today announced the acquisition of ALLCOT, a global advisory firm with a legacy of supporting climate policy, carbon markets, and high-integrity project development. This acquisition brings together two complementary forces under one shared mission: to scale science-backed, verifiable climate solutions across industries and regions. Karbon-X's leadership in emissions tracking, verified portfolios, and climate strategy combined with Allcot's legacy of policy guidance, project credibility, and regional expertise form a unified climate solutions provider with end-to-end capabilities across both voluntary and compliance markets. "This is about unlocking scale with integrity," said Chad Clovis, CEO of

Eagle Football Holdings supports Leadership Changes at Olympique Lyonnais30.6.2025 09:30:00 CEST | Press release

PALM BEACH GARDENS, FL / ACCESS Newswire / June 30, 2025 / Eagle Football Holdings Limited today confirmed its support of leadership changes which shall occur at its subsidiary Eagle Football Group (France) and Olympique Lyonnais. John Textor, Chairman and majority owner of Eagle Football Holdings, acting in his capacity as the sole director, and on behalf of the sole shareholder, of Olympique Lyonnais, today appointed Michael Gerlinger to the position of Director General (CEO), and Michele Kang to the position of Chair and President. Mr. Textor has resigned from his leadership positions at Olympique Lyonnais, in favor of the appointment of Ms. Kang and Mr. Gerlinger. Michele Kang, who is also a leading shareholder of Eagle Football Holdings, has served on the OL board since 2023, has been appointed Chair and President. She will take an active role in supporting OL's executive management, including spearheading the club's appeal process with the DNCG. Michael Gerlinger, currently Chief

CEVA Joins Windrose To Test Long-Haul EV Trucking in China27.6.2025 19:00:00 CEST | Press release

ANTWERP, BELGIUM / ACCESS Newswire / June 27, 2025 / CEVA Logistics in Greater China is coming together with Windrose, leading heavy-duty electric truck provider, to conduct a feasibility study for the deployment of long-haul electric vehicle (EV) trucking in China. This collaboration marks a significant step forward in CEVA's commitment to sustainability and its pioneering efforts to lead the sustainable development of the logistics industry. Under this partnership, CEVA and Windrose have successfully conducted trials of long-haul electric trucking, including a round-trip journey from Greater Bay Area in Guangdong to Pingxiang, Guangxi, at the China-Vietnam border, and a 5,000-kilometer journey from Shenzhen to Alashankou, at the China-Kazakhstan border. These pilot runs resulted in a remarkable carbon emissions reduction of approximately 55% on average (WTW) per GLEC framework. Based on these successes, CEVA and Windrose will continue to conduct trial runs within China to further exp

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye